Otonomy Revenue and Competitors

Claim your profile

Location

$458M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Otonomy's estimated annual revenue is currently $178k per year.(i)
  • Otonomy's estimated revenue per employee is $2,618
  • Otonomy's total funding is $458M.
  • Otonomy's current valuation is $116.7M. (January 2022)

Employee Data

  • Otonomy has 68 Employees.(i)
  • Otonomy grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière's disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus. Additionally, new therapies are required for otitis media since resistance to oral antibiotics is increasing and short-acting locally administered drugs present significant compliance challenges. Otonomy is working in partnership with leading experts in the field of otology to bring new drug therapies to patients suffering with these conditions.

keywords:Biotechnology

$458M

Total Funding

68

Number of Employees

$178k

Revenue (est)

0%

Employee Growth %

$116.7M

Valuation

N/A

Accelerator

Otonomy News

2022-04-17 - Otonomy Drug Candidate Shows Promise in Hearing-Loss Trial

Development-stage biopharmaceutical company Otonomy Inc. shares said a drug candidate showed promise in a mid-stage trial involving patients...

2022-04-17 - Otonomy reports positive results from phase 2a trial of OTO-413 in hearing loss patients

Otonomy (NASDAQ:OTIC) on Wednesday announced what it deemed to be positive results from its phase 2a trial of its formulation OTO-413 in...

2022-04-17 - Otonomy Reports Positive Top-Line Results from Phase 2a ...

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 ... SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Otonomy,...

2021-04-08 - OTONOMY, INC. Otonomy Announces Pricing of $30.1 Million Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price to th ...

2016-01-12 - Otonomy Inc. Announces Close of $115 Million Public Offering

San Diego drug developer Otonomy Inc. announced Jan 12 the closing of its $115 million public offering of stock. The previously announced public offering included 5,750,000 shares of its common stock, and an additional 750,000 shares (sold pursuant to the underwriter’s full exercise of their op ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M68-19%N/A
#2
$11M6836%N/A
#3
$12.9M686%N/A
#4
$10.1M68N/AN/A
#5
$8.9M6821%N/A